IDF Diabetes Atlas. 10th ed. Available from: https://diabetesatlas.org/ (2023)

D.J. Magliano, R.M. Islam, E.L.M. Barr, E.W. Gregg, M.E. Pavkov, J.L. Harding et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ 366, l5003 (2019)

Article  PubMed  PubMed Central  Google Scholar 

O.R. Temneanu, L.M. Trandafir, M.R. Purcarea, Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice. J. Med Life 9(3), 235–239 (2016)

CAS  PubMed  PubMed Central  Google Scholar 

Y.A. Domínguez, M. Emiliano, L. Puigi, J.H. Rodríguezi, Contribución de la Epidemiología al estudio de la diabetes mellitus. Rev. Cubana Hig. Epidemiol. 55(2), 46–50 (2017)

A.E.I. Coria, A.A. Cortés, O.F.R. de la Roche, E.C. Hernández, La Diabetes Mellitus y sus implicaciones sociales y clínicas en México y Latinoamérica Diabetes Mellitus and its Social and Clinical Implications in Mexico and Latin America. Archivos en. Med. Fam. 19(4), 91–94 (2017)

Google Scholar 

S. Katayama, M. Hatano, M. Issiki, Clinical features and therapeutic perspectives on hypertension in diabetics. Hypertension Res. 41(4), 213 (2018)

Article  Google Scholar 

G. Musso, R. Gambino, M. Cassader, G. Pagano, A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann. Med. 44(4), 375–393 (2012)

Article  CAS  PubMed  Google Scholar 

K. Yamamoto, S. Uchida, K. Kitano, N. Fukuhara, L. Okumura-Kitajima, E. Gunji et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br. J. Pharm. 164(1), 181–191 (2011)

Article  CAS  Google Scholar 

T.A. Zelniker, S.D. Wiviott, I. Raz, K. Im, E.L. Goodrich, M.P. Bonaca et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019)

Article  CAS  PubMed  Google Scholar 

T. Yamada, M. Wakabayashi, A. Bhalla, N. Chopra, H. Miyashita, T. Mikami et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc. Diabetol. 20(1), 14 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Singh, A. Kumar, Risks Associated with SGLT2 Inhibitors: An Overview. Curr. Drug Saf. 13(2), 84–91 (2018)

Article  CAS  PubMed  Google Scholar 

J.B. McGill, S. Subramanian, Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. Am. J. Cardiol. 124(Suppl 1), S45–S52 (2019)

Article  CAS  PubMed  Google Scholar 

A. Tentolouris, P. Vlachakis, E. Tzeravini, I. Eleftheriadou, N. Tentolouris. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int. J. Environ. Res. Public Health. 16, 2965 (2019)

R. Pelletier, K. Ng, W. Alkabbani, Y. Labib, N. Mourad, J.M. Gamble, Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther. Adv. Drug Saf. 12, 2042098621989134 (2021)

W.L. Bennett, N.M. Maruthur, S. Singh, J.B. Segal, L.M. Wilson, R. Chatterjee et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann. Intern Med 154(9), 602–618 (2011)

Article  PubMed  PubMed Central  Google Scholar 

B. Peene, K. Benhalima, Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes. Ther. Adv. Endocrinol. Metab. 5(5), 124–136 (2014)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, S. Sakai, Y. Samukawa, Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, phase 3 study. Curr. Med Res Opin. 30(7), 1245–1255 (2014)

Article  CAS  PubMed  Google Scholar 

H. Kakinuma, T. Oi, Y. Hashimoto-Tsuchiya, M. Arai, Y. Kawakita, Y. Fukasawa et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J. Med. Chem. 53(8), 3247–3261 (2010)

Y. Seino, K. Kaku, N. Inagaki, M. Haneda, T. Sasaki, A. Fukatsu et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Endocr. J. 62(7), 593–603 (2015)

Article  CAS  PubMed  Google Scholar 

R. Hashimoto-Kameda, K.Y. Cho, H. Nomoto, A. Nakamura, K. Omori, S. Nagai, et al. Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). Diabetes Res Clin Pract. 180, 109069 (2021)

M. Haneda, Y. Seino, N. Inagaki, K. Kaku, T. Sasaki, A. Fukatsu et al. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin. Ther. 38(1), 66–88.e20 (2016)

Article  CAS  PubMed  Google Scholar 

M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021)

Article  PubMed  PubMed Central  Google Scholar 

A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17(1), 1–12 (1996)

Article  CAS  PubMed  Google Scholar 

J.A.C. Sterne, J. Savović, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 366, l4898 (2019)

T. Shibuya, N. Fushimi, M. Kawai, Y. Yoshida, H. Hachiya, S. Ito et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diab. Obes. Metab. 20(2), 438–442 (2018)

Article  CAS  Google Scholar 

M. Sugawara, M. Fukuda, I. Sakuma, Y. Wakasa, H. Funayama, A. Kondo, et al. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study). Diabetes Ther. 14(9), (2023)

M. Shestakova, B. Kvasnikov, E. Erina, E. Isachenko, A. Andreev, Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial. BMJ Open Diab. Res Care 11(3), e003290 (2023)

Article  PubMed  PubMed Central  Google Scholar 

K. Ejiri, T. Miyoshi, H. Kihara, Y. Hata, T. Nagano, A. Takaishi, et al. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. J Am Heart Assoc. 9(16), e015103 (2020)

Y. Seino, T. Sasaki, A. Fukatsu, S. Sakai, Y. Samukawa, Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30(7), 1219–1230 (2014)

Article  CAS  PubMed  Google Scholar 

Y. Seino, T. Sasaki, A. Fukatsu, H. Imazeki, H. Ochiai, S. Sakai, Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Curr. Med. Res. Opin. 34(6), 981–994 (2018)

Article  CAS  PubMed  Google Scholar 

D. Dutta, J. Kadian, K. Mahajan, A. Dhall, M. Sharma, Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis. Diabetes Metab Syndr. 17(3), 102742 (2023)

A. Markham, S. Elkinson, Luseogliflozin: first global approval. Drugs 74(8), 945–950 (2014)

Article  CAS  PubMed  Google Scholar 

Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors - PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/35015430/ (2023)

S. Halimi, B. Vergès, Adverse effects and safety of SGLT-2 inhibitors. Diab. Metab. 40(6 Suppl 1), S28–S34 (2014)

Article  CAS  Google Scholar 

W. Xiong, M.Y. Xiao, M. Zhang, F. Chang, Efficacy and safety of canagliflozin in patients with type 2 diabetes. Medicine 95(48), e5473 (2016)

Article  CAS  PubMed  PubMed Central  Google Scholar 

R. Devi, G. Mali, I. Chakraborty, M.K. Unnikrishnan, S. Abdulsalim, Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Postgrad. Med. 129(3), 382–392 (2017)

Article  CAS  PubMed  Google Scholar 

M. Feng, H. Lv, X. Xu, J. Wang, W. Lyu, S. Fu, Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus. Medicine 98(30), e16575 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, S. Sakai, Y. Samukawa, Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30(7), 1231–1244 (2014)

Article  CAS  PubMed  Google Scholar